Table 1.
Age and sex standardised prevalence (per 100,000 population) of use of aclidinium, aclidinium/formoterol and other COPD medications among all study population, and age and sex distribution of new users among patients with COPD aged 40 years or older
| Population | CPRD, UK a (N = 3,076,149) | National Health Databases, Denmark b (N = 5,748,769) | GePaRD, Germany c (N = 16,366,351) | |||
|---|---|---|---|---|---|---|
| Users, n | Prevalence (95% CI) d | Users, n | Prevalence (95% CI) d | Users, n | Prevalence (95% CI) d | |
| Aclidinium | 3574 | 122.3 (118.2–126.3) | 2195 | 37.7 (36.1–39.3) | 13,738 | 80.4 (79.1–81.8) |
| Aclidinium/formoterol | 1579 | 53.8 (51.1–56.4) | 1788 | 30.5 (29.1–32.0) | 10,230 | 60.1 (58.9–61.3) |
| Tiotropium | 28,988 | 995.1 (983.6–1006.6) | 57,678 | 1005.3 (997.1–1013.5) | 49,845 | 295.6 (292.9–298.2) |
| Other LAMA | 11,062 | 380.6 (373.5–387.7) | 6232 | 107.2 (104.5–109.9) | 7600 | 44.5 (43.5–45.5) |
| LAMA/LABA | 6082 | 208.7 (203.5–214.0) | 35,776 | 616.4 (610.0–622.8) | 23,085 | 136.0 (134.3–137.8) |
| LABA | 6106 | 207.1 (201.9–212.3) | 35,780 | 622.4 (616.0–628.8) | 74,265 | 436.7 (433.5–439.8) |
| LABA/ICS | 113,521 | 3837.8 (3815.4–3860.2) | 156,611 | 2747.6 (2734.2–2761.1) | 436,067 | 2586.8 (2579.0–2594.6) |
| New users with COPD aged ≥ 40 years, men (%) e | ||||||
| Aclidinium | 52.0 | 47.0 | 48.8 | |||
| Aclidinium/formoterol | 55.0 | 48.7 | 52.1 | |||
| Tiotropium | 50.3 | 46.6 | 46.2 | |||
| Other LAMA | 48.8 | 46.2 | 46.9 | |||
| LAMA/LABA | 51.4 | 48.3 | 50.9 | |||
| LABA | 49.3 | 44.6 | 45.0 | |||
| LABA/ICS | 48.4 | 45.7 | 38.7 | |||
| New users with COPD aged ≥ 40 years | ||||||
| Mean (SD), median [IQR] age, years | ||||||
| Aclidinium | 69 (10.4), 69 [62–76] | 69.7 (10.5), 70 [63–77] | 67.5 (10.98), 68.0 [59–76] | |||
| Aclidinium/formoterol | 69 (10.1), 70 [62–76] | 71.0 (9.7), 71 [64–78] | 67.8 (10.31), 68 [60–75] | |||
| Tiotropium | 69 (11.2), 70 [62–78] | 71.7 (10.9), 72 [64–80] | 69.4 (11.54), 70 [61–78] | |||
| Other LAMA | 69 (10.5), 70 [62–77] | 70.4 (10.2), 71 [64–78] | 67.5 (11.03), 68 [59–76] | |||
| LAMA/LABA | 70 (10.3), 70 [63–77] | 71.7 (10), 72 [65–79] | 68.2 (10.71), 69 [61–76] | |||
| LABA | 69 (10.9), 70 [62–77] | 71.3 (10.7), 72 [64–79] | 67.0 (11.98), 67 [58–76] | |||
| LABA/ICS | 69 (11.5), 70 [61–78] | 70.3 (11.7), 71 [62–79] | 63.6 (12.89), 63 [53–74] | |||
CI confidence interval, COPD chronic obstructive pulmonary disease, CPRD Clinical Practice Research Datalink, GePaRD German Pharmacoepidemiological Research Database, ICS inhaled corticosteroids, IQR interquartile range, LABA inhaled long-acting beta2-agonist, LAMA long-acting muscarinic antagonists, SD standard deviation, UK United Kingdom
aCPRD: data on new users of study medications identified from 1 January 2015 through 31 December 2017
bNational Health Databases: data on new users of study medications identified from 4 March 2015 through 31 December 2017
cGePaRD data on new users of study medications identified from 1 February 2015 through 31 December 2015
dThe age and sex-standardised prevalence of use per 100,000 population is calculated among all users in the most recent year: 2017 for CPRD and Denmark and in 2015 for GePaRD. Standardisation based on the European standard population for 2017
eProportion of males are calculated among new users with COPD aged 40 years or older